Replies to post #640850 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

This is not fudster-extraordinaire's lingo in this post. Perhaps fudster-delusion or someone else is subbing. The customary spelling mistakes are absent. The linguistic style also is not the same.

[flipper44]

Regarding your third point. (I’m ignoring your first two points)

Let me give you a little more background.

Linda Powers, December 30, 2022.

Some years ago, some of you may remember, we had hoped to embark upon combo trials years ago, and we actually have reached conceptual agreement with several other parties, and we announced this to do -- to proceed with combo trials.

Unfortunately, from a resource standpoint just couldn't do it from a resource standpoint, and we had to just stay focused on getting our lead program to the finish line, right? But now that the Phase III trial is done and as soon as we've got the application for approval cemented, we're very eager to proceed with these combos. I will say we -- again [indiscernible] about the past, we will be looking for the terms to be favorable for Northwest and its shareholders.[/color]

We have actually -- we actually walked away from a combo trial that we could have proceeded with before. The (historic) terms were quite unfavorable with us supposed to supply everything and receive very little. So we're not going to do that. So anyway, that's our perspective on combo trials

Those hoped for combos were with CI makers.

Now, with those things in mind, let’s go to the recent Powers 10q (seven months after the above annual shareholders meeting).

The Company is in active discussions in regard to certain combination treatment regimens, and is planning for certain strategic trials with such combination treatments. August 9, 2023